RxDoctor Payments Data

Yong Wang, MD

Internal Medicine · El Monte, CANPI 1326056888

Payments from drug & device makers

$4,213in general payments, 2019–2025

Across 77 payments — averaging $54.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$901
  • GSK$840
  • Boehringer Ingelheim$505
  • Bayer$371
  • Amgen$359
  • Johnson & Johnson$310
  • plus $926 from 10 others

What the payments were for

  • Travel & lodging$150%
  • Food & beverage$4,198100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,213 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$103,041
Medicare patients
163
Services billed
1,798

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin379$228,320
KerendiaFinerenone112$67,770
MyrbetriqMirabegron123$53,708
XareltoRivaroxaban81$51,585
FarxigaDapagliflozin Propanediol86$49,599
EliquisApixaban80$48,559
ProliaDenosumab30$45,988
CreonLipase/Protease/Amylase45$45,186
TradjentaLinagliptin87$44,460
JanuviaSitagliptin Phosphate77$42,493
VascepaIcosapent Ethyl96$40,047
JanumetSitagliptin Phos/Metformin Hcl54$28,073
ZenpepLipase/Protease/Amylase28$26,528
Cyclosporine67$21,442
DapagliflozinDapagliflozin Propanediol39$20,048

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$505$272,780466 claims
AbbVieCreon, Linzess, Namzaric$225$78,161106 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta$901$68,646120 claims
BayerKerendia$371$67,770112 claims
Astellas Pharma US IncMyrbetriq$93$53,708123 claims
Johnson & JohnsonXarelto$310$51,58581 claims
PfizerEliquis$51$48,55980 claims
AmgenProlia$359$45,98830 claims
Lilly USA, LLCTrulicity$137$12,93314 claims
GSKBreo Ellipta$840$6,04815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in El Monte

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →